| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2977163 | Journal of Nuclear Cardiology | 2007 | 14 Pages |
Abstract
This phase 3 trial shows that regadenoson provides diagnostic information comparable to a standard adenosine infusion. There were no serious drug-related side effects, and regadenoson was better tolerated than adenosine.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Ami E. MD, FACC, Timothy M. MD, FACC, Luiz MD, Brent PhD, Manuel D. MD, FACC, Robert C. MD, FACC, Hsiao MD, FACC, John J. MD, FACC, Ann PhD, S. Richard MD, FACC, João MD, Whedy PhD, ADVANCE MPI Investigators ADVANCE MPI Investigators,